Ms. Ziemba joined CTI BioPharma in September 2012 to lead CTI’s Pharmacovigilance function and was promoted to Vice President of Pharmacovigilance and Quality in November 2016. In January 2018 she was promoted to Vice President of Clinical Operations, Pharmacovigilance and Quality. Ms. Ziemba leads CTI BioPharma’s clinical operations team(s) responsible for study delivery, oversees commercial and clinical pharmacovigilance and CTI’s Quality Management System.
Ms. Ziemba has over 25 years of global clinical development, and commercial pharmacovigilance success across therapeutic areas including oncology, immunoscience, neurology and ophthalmology. She has successfully built and led Pharmacovigilance functions to support mid and late stage clinical development, product approval and global product launches. Prior to joining CTI BioPharma, Ms. Ziemba held senior management and leadership positions at Acucela, ZymoGenetics, Elan and Immunex. Ms. Ziemba holds a B.S in Chemistry and Physics from Michigan State University, and a Master’s in Business Administration from Colorado Technical University.